KRAS G12D MUTATIONS
Clinical trials for KRAS G12D MUTATIONS explained in plain language.
Never miss a new study
Get alerted when new KRAS G12D MUTATIONS trials appear
Sign up with your email to follow new studies for KRAS G12D MUTATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted pill takes on Hard-to-Treat pancreatic cancer
Disease control Recruiting nowThis Phase 2 trial is testing an oral drug called RNK08954 in 60 people with metastatic pancreatic cancer that has a specific genetic change (KRAS G12D mutation). The drug is taken daily and aims to slow tumor growth. Researchers will measure how long the cancer stays under contr…
Matched conditions: KRAS G12D MUTATIONS
Phase: PHASE2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New hope for Hard-to-Treat cancers: targeted drug enters human trials
Disease control Recruiting nowThis study tests an experimental drug called GFH375 in people with advanced solid tumors that have a specific genetic change (KRAS G12D). The goal is to see if the drug is safe, tolerable, and can shrink tumors. About 407 adults aged 18 to 75 with advanced cancers like lung or pa…
Matched conditions: KRAS G12D MUTATIONS
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC